Monday June 26th 2017

Posts Tagged ‘Paolo Zamboni’

MS patients going in droves for unproven therapy

MS patients going in droves for unproven therapy

Scores, even hundreds of people with multiple sclerosis have in the last half-year or so undergone a procedure many hope will cure or at least improve their disease symptoms. And with each passing week, more are travelling abroad to have the untested therapy, which most [Read More]

From M.S. Patients, Outcry for Unproved Treatment

From M.S. Patients, Outcry for Unproved Treatment

For her first appointment with Dr. Daniel Simon, Neelima Raval showed up with a rolling file cabinet full of documents. She had downloaded every word written by or about Dr. Paolo Zamboni, a vascular surgeon from Italy with a most unorthodox theory about multiple sclerosis. [Read More]

Clinical trial in Buffalo to test ‘liberation treatment’

Clinical trial in Buffalo to test ‘liberation treatment’

Researchers at the University at Buffalo are about to launch North America’s first clinical trial to test the “liberation treatment,” an experimental therapy designed to halt the symptoms of multiple sclerosis. The landmark prospective, randomized, [Read More]

 Page 4 of 10  « First  ... « 2  3  4  5  6 » ...  Last » 

Latest Topics

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

BACKGROUND: In people with Multiple Sclerosis (pwMS), balance assessment is essential in estimating the risk of falls, [Read More]

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

The European Medicines Agency ’ s Committee for Medicinal Products for Human Use recommends approval of cladribine to [Read More]

Germany’s Merck gets EU backing for oral MS drug

Germany’s Merck gets EU backing for oral MS drug

FRANKFURT (Reuters) - Germany's Merck KGaA has won a key recommendation to become a late entrant to the market for oral [Read More]

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

Roche announced today that new post-hoc analyses from the OCREVUS ™ (ocrelizumab) Phase III clinical trial programme [Read More]

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

/About-the-Society/News/Society-Hosts-Joint-Congressional-Briefing-on-the [Read More]